CA3162962A1 - Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer - Google Patents

Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer Download PDF

Info

Publication number
CA3162962A1
CA3162962A1 CA3162962A CA3162962A CA3162962A1 CA 3162962 A1 CA3162962 A1 CA 3162962A1 CA 3162962 A CA3162962 A CA 3162962A CA 3162962 A CA3162962 A CA 3162962A CA 3162962 A1 CA3162962 A1 CA 3162962A1
Authority
CA
Canada
Prior art keywords
fgfr
patient
inhibitor
fgfr3
erdafitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3162962A
Other languages
English (en)
French (fr)
Inventor
Manish MONGA
Mahadi Ali BAIG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3162962A1 publication Critical patent/CA3162962A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3162962A 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer Pending CA3162962A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US62/975,547 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US63/018,914 2020-05-01
US202063118475P 2020-11-25 2020-11-25
US63/118,475 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
CA3162962A1 true CA3162962A1 (en) 2021-08-19

Family

ID=74666675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3162962A Pending CA3162962A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Country Status (14)

Country Link
US (1) US20230110113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513704A (cg-RX-API-DMAC7.html)
KR (1) KR20220140781A (cg-RX-API-DMAC7.html)
CN (1) CN115103678A (cg-RX-API-DMAC7.html)
AU (1) AU2021220285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015827A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162962A1 (cg-RX-API-DMAC7.html)
IL (1) IL295514A (cg-RX-API-DMAC7.html)
JO (1) JOP20220182A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009905A (cg-RX-API-DMAC7.html)
PH (1) PH12022552093A1 (cg-RX-API-DMAC7.html)
TW (1) TW202143970A (cg-RX-API-DMAC7.html)
WO (1) WO2021160764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
JP2025506402A (ja) * 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ.ベー. 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン
WO2023159216A1 (en) * 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
IL322667A (en) * 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
KR20250148646A (ko) * 2023-02-13 2025-10-14 얀센 파마슈티카 엔브이 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
CN121891539A (zh) * 2026-02-06 2026-04-21 深圳大学 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
JP2023513704A (ja) 2023-04-03
PH12022552093A1 (en) 2023-11-29
JOP20220182A1 (ar) 2023-01-30
KR20220140781A (ko) 2022-10-18
MX2022009905A (es) 2022-08-25
JP2026097934A (ja) 2026-06-16
CN115103678A (zh) 2022-09-23
EP4103185A1 (en) 2022-12-21
WO2021160764A1 (en) 2021-08-19
TW202143970A (zh) 2021-12-01
IL295514A (en) 2022-10-01
US20230110113A1 (en) 2023-04-13
AU2021220285A1 (en) 2022-10-06
BR112022015827A2 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2020253827B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
AU2020223467B2 (en) Cancer treatment
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
AU2024222187A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240729

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250212

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251110

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260115

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260115